Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Long-Term Deferred Tax (2022 - 2025)

Sunshine Biopharma (SBFM) has disclosed Long-Term Deferred Tax for 4 consecutive years, with $92234.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Deferred Tax changed N/A year-over-year to $92234.0, compared with a TTM value of $92234.0 through Sep 2025, changed N/A, and an annual FY2024 reading of $92234.0, down 47.82% over the prior year.
  • Long-Term Deferred Tax was $92234.0 for Q3 2025 at Sunshine Biopharma, roughly flat from $92234.0 in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $176764.0 in Q4 2023 and bottomed at $43032.0 in Q4 2022.
  • Average Long-Term Deferred Tax over 4 years is $98122.0, with a median of $92234.0 recorded in 2024.
  • The sharpest move saw Long-Term Deferred Tax skyrocketed 310.77% in 2023, then tumbled 47.82% in 2024.
  • Year by year, Long-Term Deferred Tax stood at $43032.0 in 2022, then surged by 310.77% to $176764.0 in 2023, then crashed by 47.82% to $92234.0 in 2024, then changed by 0.0% to $92234.0 in 2025.
  • Business Quant data shows Long-Term Deferred Tax for SBFM at $92234.0 in Q3 2025, $92234.0 in Q2 2025, and $92234.0 in Q1 2025.